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Introduction 
 
Warfarin is well known both for being an effec-
tive oral anticoagulant and for its difficulties in 
dosing due to its narrow therapeutic range and 
the wide interindividual variability in dosing be-
tween patients.  Although factors such as age, 
sex, race, and weight can contribute to this inter
-patient variability, dosing algorithms that in-
clude genotyping variants in the cytochrome 
P450, family 2, subfamily C, polypeptide 9 
(CYP2C9) and vitamin K epoxide reductase 
complex, subunit 1 (VKORC1)  genes may aid in 
achieving the optimal warfarin dose [1, 2]. A 
number of laboratory developed tests and com-
mercial products for genotyping for warfarin 
dose selection have been introduced in recent 
years [3]. Clinical practice has been slow to 
adopt genotyping in the care of patients being 
treated with warfarin due to clinical concerns 
over insufficient evidence supporting the clinical 
utility of such testing and a paucity of evidence-
based guidelines on how to use genotyping re-
sults to optimize a patient’s warfarin dosing. 
New genotype-based dosing guidelines in the 
warfarin product insert and results from com-
pleted and ongoing prospective studies may 
result in increased utilization of genotyping to 
predict warfarin sensitivity [4]. 
 
The specific variants genotyped for predicting 
warfarin sensitivity include the single nucleotide 
polymorphisms (SNPs) in CYP2C9 and VKORC1 
can be performed in the clinical setting to aid in 
the dosing of the oral anticoagulant, warfarin. 
Both the R and S enantiomer of warfarin com-
petitively inhibits VKORC1 (the S enantiomer 
being the most potent) and the S-warfarin is 
mainly metabolized by CYP2C9 making these 
two genes and their genetic variants key con-
tributors, along with other factors such as age, 
weight, race and diet, to the wide variability in 
the optimal daily warfarin dose between pa-
tients. The CYP2C9 and VKORC1 SNPs that are 
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Abstract:  Genetic testing for common variants in the CYP2C9 and VKORC1 genes may provide useful clinical informa-
tion to guide dosing patients receiving oral warfarin.  Specifically, the CYP2C9*2, CYP2C9*3 and either the VKORC1 -
1639 G>A or VKORC1 1173C>T polymorphisms can be used to help predict an approximate warfarin maintenance 
dose needed for a particular patient.  Although clinical uptake and use of this genotyping has been slow, an increas-
ing body of literature provides evidence of the clinical utility of supplementing traditional warfarin dosing algorithms 
with a pharmacogenetic approach.  The availability of multiple methods for clinical genotyping provides the opportu-
nity for molecular diagnostic laboratories to introduce genotyping assays tailored to their specific needs based on 
variables such as testing volumes, staffing, available instrumentation and needed turnaround times.  Three assays 
(Invader, Verigene and TaqMan) designed to detect three genetic variations associated with warfarin dosing are 
evaluated and compared as potential clinical tests to assist in patient care.  Identical genotypes were reported by 
each assay for all samples tested but the assays were found to differ in turnaround time, approval status by the U.S. 
Food and Drug Administration (FDA), requirements for amount of input genomic DNA and other logistical factors that 
might make each assay more favorable in different settings. 
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established as being clinically significant for 
determining warfarin dosing include CYP2C9*2 
(NP_000762.2:p.Arg144Cys, rs1799853), 
CYP2C9*3 (NP_000762.2:p.Ile359Leu, 
rs1057910), which yield reduced enzyme activ-
ity, and two VKORC1 SNPs in complete linkage 
disequilibrium, normally referred to as VKORC1 
1173C>T (rs9934438; NT_010393.15: 
g.22417957G>A) and VKORC1 -1639G>A 
(rs9923231; NT_010393.15: g.22420768C>T) 
[5].  The VKORC1 SNPs are non-coding and 
therefore are thought to affect optimal warfarin 
dose by altering VKORC1 expression [6]. 
 
Although methods for sequencing the regions of 
the CYP2C9 and VKORC1 genes containing the 
clinically significant SNPs, such as Sanger se-
quencing, could potentially be used in the clini-
cal setting, most molecular diagnostic laborato-
ries choose alternate methods for routine geno-
typing applications due to regulatory and quality 
assurance issues as well as financial con-
straints and a need for rapid turnaround times 
[7]. A large number of molecular testing strate-
gies exist for determining the genotype of an 
individual at one or more loci [8]. The antici-
pated need for warfarin sensitivity genotyping 
led to numerous commercial and laboratory-
developed clinical assays for CYP2C9*2, 
CYP2C9*3 and either VKORC1 1173C>T or -
1639G>A genotyping. Here two commercially-
developed assays and one research use only 
(RUO)-based in house laboratory-developed war-
farin genotyping assay are evaluated for use in 
a molecular testing laboratory. 
 
Materials and methods 
 
DNA samples 
 
A total of fifty human genomic DNA samples 
isolated from de-identified peripheral blood 
specimens were separated into two sets for use 
in this study. DNA sample set A consisted of 24 
samples isolated using the MagNA Pure Com-
pact (Roche Diagnostics, Indianapolis, IN) and 
set B consisted of 26 DNA samples isolated 
using the EZ1 BioRobot (QIAGEN Inc, Valencia, 
CA). DNA concentration was measured using 
spectrophotometry (A260) and appropriate dilu-
tions were made when necessary for the In-
vader and TaqMan assays. 
 
Genotyping methods 
 
Common SNPs in CYP2C9 and VKORC1 were 
analyzed using three different methodologies: 
the Verigene® System (Nanosphere, Inc., 
Northbrook, IL), Invader chemistry (Third Wave 
Technologies, Madison, WI; now owned by 
Hologic), and TaqMan PCR assays performed on 
the 7500 Fast Real-time PCR System (Applied 
Biosystems, Carlsbad, CA). Specifically, CYP2C9 
was genotyped with respect to the CYP2C9*1 
(wild-type), CYP2C9*2 and CYP2C9*3 alleles 
and one of two VKORC1 SNPs in strong linkage 
disequilibrium by each method. Because of the 
strong linkage disequilibrium between the two 
VKORC1 variants and to allow for inter-assay 
comparisons, when a variant allele was de-
tected at one locus it was assumed that a vari-
ant allele was also present at the other locus. 
DNA samples in set A were genotyped by all 
three methods and samples in set B were only 
genotyped using the Invader and TaqMan as-
says. 
 
Verigene® genotyping 
 
The Verigene® Warfarin Metabolism Nucleic 
Acid Test (IVD) (Nanosphere, Inc., Northbrook, 
IL) is an in vitro diagnostic (IVD) assay approved 
by the FDA for clinical use. Each single-use, self-
contained test cartridge can be run in a random 
access format and contains a set of fluidic 
chambers with reagents for processing the at-
tached low-density microarray with replicate 
features of oligonucleotide probes designed to 
hybridize to the specific alleles to identify 
CYP2C9*2, CYP2C9*3 and the VKORC1 poly-
morphism 1173C>T. Genomic DNA samples 
were analyzed without any PCR amplification 
steps by pipetting 25 µL of genomic DNA 
(recommended concentration of 40-400 ng/µL) 
into a single test cartridge with 25 µL of sample 
buffer. Cartridges were then inserted into a Veri-
gene® Processor until the automated hybridiza-
tion, detection and wash steps were completed. 
After removing the reagent pack from each car-
tridge, the microarrays were then analyzed in a 
Verigene® Analyzer which automatically makes 
genotyping calls of wild-type (homozygous), het-
erozygous or mutant (homozygous) for each of 
the polymorphisms [9-11].  
 
Invader ®genotyping 
   
Invader® Warfarin Analyte-Specific Reagents 
(ASRs) were used for CYP2C9*2, CYP2C9*3 
and VKORC1 -1639G>A genotyping. These re-
agents were discontinued after the increased 
enforcement by the FDA of policies defining and 
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regulating the use of ASRs in diagnostic labora-
tories but individual researchers may be able to 
develop similar Invader® testing strategies using 
custom designed reagents with general purpose 
reagents. Each genomic DNA sample (5 µL; 10-
80 ng/µL) was first subjected to three separate 
15-cycle PCRs (one for each SNP) and the re-
sulting DNA was then used in isothermal In-
vader® reactions containing Invader® probes 
and FRET cassettes on a 96-well plate[12].  
Signal amplification during each Invader® reac-
tion resulted in increased fluorescent signal for 
one or both alleles being interrogated in each 
reaction. Fluorescence for each allele was then 
measured on a Tecan GENiosFL plate reader 
and calls of either heterozygous or homozygous 
for one of the two alleles for each SNP were 
determined based on the relative fluorescent 
signals. Synthetic DNA controls representing 
heterozygous samples and “no template” water 
blanks were included for each SNP.  
 
TaqMan® genotyping 
 
For each genomic DNA samples three separate 
TaqMan® PCR reactions were carried out on a 
96-well plate in a 7500 Fast Real-time PCR Sys-
tem using 1 µL of DNA (5-20 ng/µL). Each PCR 
contained a pair of oligonucleotide primers and 
two TaqMan® probes predesigned to hybridize 
specifically to the two alleles for each SNP 
(CYP2C9*2, Assay ID: C__25625805_10; 
CYP2C9*3, Assay ID: C__27104892_10; 
VKORC1 1173C>T, Assay ID: C__30204875 
_10) (Applied Biosystems, Carlsbad, CA). After 
40 PCR cycles the relative fluorescence values 
for each allele were plotted against each other 
on an allelic discrimination plot with the 7500 
version 2 software to determine CYP2C9*2, 
CYP2C9*3 and VKORC1 1173C>T genotypes. 
Each run included previously genotyped ge-
nomic DNA controls representing each allele 
and “no template” water blanks for each of the 
three loci tested. 
 
Nomenclature 
 
CYP2C9*1 is reference or wild-type allele and in 
this study refers to CYP2C9 alleles other than 
*2 (s1799853) or *3 (rs1057910) 
(www.cypalleles.ki.se/cyp2c9.htm). Due to the 
complete linkage disequilibrium between the 
1173C>T (rs9934438) and -1639G>A 
(rs9923231) SNPs for VKORC1, haplotype des-
ignations (A or B) described elsewhere [1] are 
used to simplify comparisons between assays 
targeting different VKORC1 loci. 
 
Results 
 
Genotyping of MagNA pure DNA samples 
 
CYP2C9 and VKORC1 genotypes were obtained 
by the Verigene®, Invader® and TaqMan® assays 
for all 24 genomic DNA samples extracted using 
the MagNA Pure Compact System(set A). One of 
these samples, however, had to be repeated 
with the Verigene® assay due to an initial “no 
call” result. 100% concordance in genotype re-
sults was observed between the three assays 
for all three loci examined. With respect to 
CYP2C9, the samples in set A included 16 
(66.7%) with a *1/*1 genotype, 4 (16.7%) with 
a *1/*2 genotype, 3 (12.5%) with a *1/*3 
genotype and a single sample (4%) homozygous 
for CYP2C9*2 (*2/*2).  No *2/*3 or *3/*3 
genotypes were observed. VKORC1 haplotypes 
in this set included 3 AA (12.5%), 12 AB (50%) 
and 9 BB (37.5%) DNA samples. 
 
Genotyping of EZ1 DNA samples 
 
DNA samples isolated using the EZ1 BioRobot 
(set B) were tested using the Invader® and 
TaqMan® assays (Table 1). Genotypes were de-
fined for all 26 samples without the need for 
any repeat testing. Samples in set B were also 
found to have 100% concordance between the 
two genotyping methods for all three loci in 
CYP2C9 and VKORC1. Only *1/*1, *1/*2 and 
*1/*3 genotypes were detected in CYP2C9 in 
16 (61.5%), 8 (30.8%) and 2 (7.7%) of the 26 
samples, respectively. VKORC1 haplotypes AA, 
AB and BB were detected in 2 (7.7%), 16 
(61.5%) and 8 (30.8%) of the 26 samples, re-
spectively. 
 
Assay comparisons 
 
Selected features for each assay were evalu-
ated and compared in Table 1.  The Verigene® 
assay required the most DNA by volume and 
concentration (10-80 ng/µL, 25 µL) the largest 
volume and total amount while the TaqMan® 
assay required much less DNA (5-20 ng/
µL,1uL). Other comparisons were complicated 
due to lack of sample batching needed for the 
Verigene assay. The approximate turnaround 
times (TATs) for the Verigene®, Invader® and 
TaqMan® assays of 1.5, 4.0 and 2.0 hours, re-
Warfarin genotyping using three different platforms  
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spectively were based on running a single sam-
ple with appropriate controls. Additional sam-
ples (up to the maximum batch sizes shown) 
were found to have very little effect on the turn-
around times for the Invader® and TaqMan® 
assays but each additional sample run at the 
same time using the Verigene® assay added 5-
10 minutes to the turnaround time for the entire 
batch.  The relative number of manipulations 
shown for each assay reflects the need for only 
two pipetting steps per sample for the Veri-
gene® assay, three different PCRs per sample/
control for the TaqMan® assay and three PCRs 
and three Invader® reactions per sample/
control for the Invader® assay. 
 
Allelic frequencies 
 
The genotypes of all fifty samples, set A and B 
combined (Table 2), were used to calculate ob-
served allelic frequencies which were found to 
be similar to the expected frequencies for the 
CYP2C9 and VKORC1 SNPs, further confirming 
the accuracy of the assays used. The CYP2C9 
*2 and *3 allelic frequencies based on these 
50 samples were 0.14 and 0.05, respectively. 
The combined allelic frequencies for the 
VKORC1 haplotypes A and B were 0.38 and 
0.62, respectively.  
 
Discussion 
 
The Verigene®, Invader®, and TaqMan® assays 
used in this study were all suitable methods for 
genotyping the CYP2C9*2, CYP2C9*3 and 
VKORC1 1173C>T or -1639G>A SNPs that con-
tribute to patient-to-patient variability in optimal 
warfarin dosing as demonstrated in the 100% 
concordance observed between assays.  Addi-
tionally, the allelic frequencies for CYP2C9*2, 
CYP2C9*3 and the VKORC1 variant were com-
parable to previous reports and other public 
information (www.ncbi.nlm.nih.gov/projects/
SNP/) for predominantly caucasian populations, 
supporting the accuracy of the genotyping re-
sults [2, 5, 8].   
 
Although some CYP2C9 genotypes were under-
represented or not present in this study 
(homozygous for CYP2C9 *2 or *3), the repro-
ducibility of results for control samples included 
in each run for the Invader® and TaqMan® as-
says or run previously for the Verigene® assay 
(vendor-supplied DNA used during initial per-
formance verification) indicate excellent per-
formance across genotypes for all three assays.   
 
The IVD status of the Verigene® assay may 
make it more favorable to many laboratories for 
clinical diagnostic use in the United States. De-
Table 1.  Comparative Features of the Verigene®, Invader®, and TaqMan® Genotyping Assays. 
  Verigene® Invader® TaqMan® 
DNA Requirements 10-80 ng/μL 10-80 ng/μL 5-20 ng/μL 
(25 μL) (5 μL) (1 μL) 
Post DNA Extraction Turn-
around Time 
1.5 hr 4 hr 2 hr 
Manipulations Needed Minimal Many Intermediate 
Maximum Batch Size No need for batching 26 28 
Unique Features Random Access; ASR Reagents; No post-PCR 
 No PCR; Discontinued Manipulation 
 Automated Calls;   
 IVD Status   
ASR=Analyte Specific reagent; IVD=in vitro diagnostic 
Table 2. CYP2C9 Genotypes and VKORC1  
Haplotypes identified 
Gene Genotype or Hap-lotype 
Number of 
samples 
CYP2C9 *1/*1 32 
  *1/*2 12 
  *1/*3 5 
  *2/*2 1 
      
VKORC1 AA 5 
  AB 28 
  BB 17 
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pending on the specific application or testing 
algorithm, the shorter turnaround time (TAT) of 
this assay (approximately 90 min after DNA iso-
lation) may also be a influential factor for labo-
ratories performing testing for physicians who 
would like to use the genotype information to 
guide optimal warfarin dosing for patients be-
ginning warfarin therapy. The Verigene® assay, 
which can be performed with only two pipetting 
steps and no data analysis on the part of the 
user, requires less technical expertise than the 
other assays and could be implemented with 
little difficulty in clinical laboratories without 
extensive experience in molecular techniques. 
Although calculated costs per sample can be 
much higher for the Verigene® assay, the added 
technologist ‘hands-on’ time and dependence 
on multiple controls per run for the Invader® 
and TaqMan® assay could make the cost of per-
forming the Verigene® assay more reasonable, 
especially if single samples or small batches are 
run [3, 13].   
 
The current non-availability of commercial re-
agents for a warfarin genotyping Invader® assay 
would make the implementation of clinical war-
farin genotyping with Invader® chemistry diffi-
cult for most laboratories without experience in 
designing this type of assay. Although other 
comparisons of warfarin genotyping methodolo-
gies using the Verigene® and Invader® assays 
exist in the literature [3, 13] this study also 
evaluates TaqMan® PCR genotyping assays. In 
the research setting or when larger batches are 
processed, the TaqMan® assay could be a more 
feasible choice for warfarin genotyping, espe-
cially in laboratories already equipped with real-
time PCR instruments, such as the 7500 instru-
ment, capable of genotyping with TaqMan® PCR 
assays. 
 
The debate and uncertainty, since the initial 
2007 warfarin relabeling, surrounding the inter-
pretation and use of warfarin genotype in man-
aging patients being treated with this anti-
coagulant, has resulted in minimal adoption of 
routine clinical genotyping for warfarin dosing 
guidance. In January 2010, the FDA further 
modified the warfarin product inserts to not only 
mention the potential effect of CYP2C9 and 
VKORC1 polymorphisms on warfarin dosing but 
to also include more detailed dosing guidance 
for the various genotypes in the form of a table 
(www.fda.gov/Safety/MedWatch/Safety Infor-
mation/ucm201100.htm) (packageinserts.bms. 
com/pi/pi_coumadin.pdf). Whether or not war-
farin genotyping becomes a routine clinical 
laboratory test, the time and effort invested by 
various clinical molecular diagnostic companies 
and molecular laboratories into genotyping as-
says such as those described in this study may 
serve to prepare the health care industry for 
future genotyping applications within and out-
side the field of pharmacogenetics.  
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650-4845, E-mail: gregory.j.tsongalis@hitchcock.org 
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